Merck & Co., Inc. (MRK)
Merck Has Many Bullish Attributes (Technical Analysis)
Merck presents a bullish investment case with strong valuation, improving grades, and a well-supported, growing dividend. MRK's technical setup is positive: price trades above its 30-week EMA, momentum indicators are bullish, and volume shows institutional accumulation. Since its May low, the company has outperformed the S&P 500, with relative strength now trending higher and above its 30-week EMA.
MRK to Buy Cidara for $9.2B: Focus on Buyout Spree Heading Into 2026
Merck's $9.2 billion proposed Cidara acquisition will add CD388 to the pipeline, boosting the respiratory portfolio and fueling its ongoing strategic M&A momentum.
MRK Up Nearly 10% in a Month: Should You Buy, Sell or Hold the Stock?
Merck rebounds on pipeline wins and a $9.2B Cidara deal, but mixed trends and Keytruda risks keep investors weighing next moves.
Merck And Royal Gold Among 13 Companies To Announce Annual Increases In Second Half Of November
This is my latest article, where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. Dividend growth picked up from companies in the first half of November, with 6 companies announcing 10%+ increases, including ADP, Roper Technologies, Atmos, and Snap-on. Other notable companies expecting dividend hikes include Motorola Solutions, McCormick, and Raymond James, each with robust earnings trends.
Merck & Co., Inc. (MRK) Presents at 7th Annual Healthcare Symposium Transcript
Merck & Co., Inc. ( MRK ) 7th Annual Healthcare Symposium November 14, 2025 11:55 AM EST Company Participants Michelle Kehily Conference Call Participants Elena Meng Michael Paas Stephen S. Morse Magdalena Sobieszczyk Presentation Unknown Attendee So our final panel of the day is about vaccines.
Here's Why Merck (MRK) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Merck & Co., Inc. (MRK) Shareholder/Analyst Call Transcript
Merck & Co., Inc. ( MRK ) Shareholder/Analyst Call November 9, 2025 7:01 PM EST Company Participants Peter Dannenbaum - Vice President of Investor Relations Dean Li - Executive VP & President of Merck Research Laboratories Joerg Koglin - Senior VP & Head of General Medicine - Global Clinical Development Jannie Oosthuizen - Senior VP & President Merck U.S. Human Health Conference Call Participants Taylor Hanley - JPMorgan Chase & Co, Research Division Daina Graybosch - Leerink Partners LLC, Research Division Nick Jennings - Goldman Sachs Group, Inc., Research Division Malcolm Hoffman - BMO Capital Markets Equity Research Vamil Divan - Guggenheim Securities, LLC, Research Division Courtney Breen - Sanford C. Bernstein & Co., LLC.
Will Keytruda Aid MRK's Growth in 2026 After a Subdued Q3?
Merck leans on Keytruda's expanding cancer indications and new SC formulation to sustain growth momentum into 2026 after soft sales in Q3.
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Merck (MRK) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
MRK Beats Q3 Earnings Estimates, Narrows 2025 Sales View, Stock Down
Merck tops Q3 earnings and revenue estimates on strong oncology, new drugs and animal health sales, while narrowing its 2025 revenue outlook.
Merck & Co., Inc. (MRK) Q3 2025 Earnings Call Transcript
Merck & Co., Inc. ( MRK ) Q3 2025 Earnings Call October 30, 2025 9:00 AM EDT Company Participants Peter Dannenbaum - Vice President of Investor Relations Robert Davis - Chairman, President & CEO Caroline Litchfield - Executive VP & CFO Dean Li - Executive VP & President of Merck Research Laboratories Conference Call Participants Asad Haider - Goldman Sachs Group, Inc., Research Division Geoffrey Meacham - Citigroup Inc., Research Division Akash Tewari - Jefferies LLC, Research Division Evan Seigerman - BMO Capital Markets Equity Research Daina Graybosch - Leerink Partners LLC, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Carter Gould - Cantor Fitzgerald & Co., Research Division Terence Flynn - Morgan Stanley, Research Division Umer Raffat - Evercore ISI Institutional Equities, Research Division Courtney Breen - Sanford C. Bernstein & Co., LLC.
